Study on Determine the Utilisation and Clinical Outcomes of Evusheld in COVID-19 PrEP in China - CLEAR

Study identifier:D8850R00019

ClinicalTrials.gov identifier:NCT05917951

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Study on Clinical Use of Evusheld (AZD7442) in the Real-world Setting – A Multi‑centre, Single-arm, Observational Study to Determine the Utilisation and Clinical Outcomes of Evusheld in China

Medical condition

COVID-19

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

248

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 24 Dec 2022
Primary Completion Date: 20 Jul 2023
Study Completion Date: 20 Jul 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria